Elefante Mark B bought a new position in Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,800 shares of the company’s stock, valued at approximately $617,000.
Other large investors also recently made changes to their positions in the company. Barrow Hanley Mewhinney & Strauss LLC purchased a new stake in shares of Merck KGaA in the second quarter valued at $942,087,000. Bank of Nova Scotia purchased a new stake in Merck KGaA in the 2nd quarter valued at about $281,696,000. Danske Bank A S acquired a new position in shares of Merck KGaA during the 2nd quarter valued at about $276,535,000. Korea Investment CORP acquired a new stake in shares of Merck KGaA in the second quarter worth approximately $239,191,000. Finally, Great Lakes Advisors LLC purchased a new stake in Merck KGaA in the second quarter valued at approximately $183,444,000. Hedge funds and other institutional investors own 0.10% of the company’s stock.
Merck KGaA Price Performance
Shares of MKGAF opened at $163.21 on Monday. The firm has a market cap of $21.09 billion, a PE ratio of 24.92 and a beta of 0.96. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The company’s fifty day moving average is $162.62 and its two-hundred day moving average is $148.44. Merck KGaA has a fifty-two week low of $116.68 and a fifty-two week high of $175.56.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Featured Articles
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
